Advertisement

PharmacoEconomics & Outcomes News

, Volume 825, Issue 1, pp 25–25 | Cite as

Niraparib not cost effective for platinum-sensitive ovarian cancer

Clinical study
  • 7 Downloads

Reference

  1. Dottino JA, et al. U.S. Food and Drug Administration-Approved Poly (ADP-Ribose) Polymerase Inhibitor Maintenance Therapy for Recurrent Ovarian Cancer: A Cost-Effectiveness Analysis. Obstetrics and Gynecology : 11 Mar 2019. Available from: URL: http://doi.org/10.1097/AOG.0000000000003171

Copyright information

© Springer International Publishing AG 2019

Personalised recommendations